When is Ascendis Pharma AS's (ASND) next earnings report?

Ascendis Pharma AS's next earnings report is expected on July 26, 2026 (59 days away). View ASND's historical earnings reactions and AI-powered earnings trade plan on Trend Edge at https://trendedge.app/asset/ASND

What is Ascendis Pharma AS's (ASND) market cap?

Ascendis Pharma AS has a market cap of $15.21B, classifying it as a large-cap Healthcare stock. Trend Edge tracks ASND's institutional ownership (104.0%), insider transactions, and proprietary indicators.

Is Ascendis Pharma AS (ASND) founder-led?

Yes — Ascendis Pharma AS is founder-led. Current founder leadership: Jan Møller Mikkelsen (President and CEO). Founder-led companies are tracked separately by Trend Edge as a proprietary indicator.

What is ASND's Trend Edge Score?

ASND's current Trend Edge Score is 63.2. The Trend Edge Score is a proprietary technical indicator combining weekly trend strength, momentum, and volume signals into a single value used to rank long position setups across thousands of tracked stocks.

How has ASND historically reacted to earnings?

Over the last 45 earnings events, ASND has averaged a 0.04% return in the week following earnings, with a 44.44% win rate. Best 1-week reaction: +22.69%. Worst: -16.15%. Full earnings reaction breakdown across gap, 1-day, 2-week, and 1-month timeframes available on Trend Edge.

What is the average analyst price target for ASND?

16 Wall Street analysts have an average price target of $296.77 on ASND, implying 23.8% upside from the current price of $239.65.

ASND Stock Analysis — Ascendis Pharma AS · Founder-Led

About Ascendis Pharma AS

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. Read full Trend Edge analysis →

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
IPO Date: January 28, 2015
Headquarters: Tuborg Boulevard 12, Hellerup, Denmark, 2900
Website: https://ascendispharma.com
Employees: 1,189

Key Metrics

Current Price	$239.65
Market Cap	$15.21B
Float	62.1M
Shares Outstanding	61.8M
P/E (Forward)	13.97
P/E (TTM)	28.05
Price/Sales (TTM)	17.57
vs. Analyst Target	+23.8% to analyst PT
Profit Margin	57.28%
Operating Margin (TTM)	10.06%
Revenue (TTM)	$866M
Dividend Rate	None
Analyst Target Price	$296.77 (16 analysts)

Financial History

Annual Revenue & Earnings History

Year	Revenue	Net Income	Gross Profit	EBITDA
2020	$7.0M	-$419M	$7.0M	-$408M
2021	$7.8M	-$384M	$4.3M	-$365M
2022	$51.2M	-$583M	$39.0M	-$529M
2023	$267M	-$481M	$222M	-$411M
2024	$364M	-$378M	$319M	-$290M
2025	$692M	-$219M	$589M	-$114M

Recent Quarterly Revenue & Net Income

Quarter	Revenue	Net Income
Jun 2025	$158M	-$38.9M
Sep 2025	$214M	-$61.0M
Dec 2025	$245M	-$33.2M
Mar 2026	$251M	$640M

Insider Ownership	0.8%
Institutional Ownership	104.0%
Short Float	4.6%
% of All Funds Holding	3.07%
Number of Funds Holding	252

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

Timeframe	SMA	Value	Trend Context
Weekly	10-Week SMA	$234.60	Near-term / short-term trend
Weekly	40-Week SMA	$217.20	Medium-term trend
Weekly	80-Week SMA	$186.34	Cyclical trend (business cycle)
Weekly	200-Week SMA	$143.83	Secular trend (multi-year)
Monthly	10-Month SMA	$217.76	Near-term monthly trend
Monthly	20-Month SMA	$184.83	Medium-term monthly trend
Monthly	40-Month SMA	$150.47	Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price Level	Type	Volume Ratio	Age
$172.00	support	1.13x	8 months ago
$157.00	support	1.13x	12 months ago
$128.00	support	1.04x	14 months ago
$125.00	support	1.10x	17 months ago

Historical Earnings Reactions (45 events)

Timeframe	Avg Return	Median	Win Rate	Best	Worst
Gap	-0.41%	0.06%	53.33%	5.49%	-16.75%
1 Day	0.77%	0.97%	62.22%	10.16%	-11.27%
1 Week	0.04%	-0.91%	44.44%	22.69%	-16.15%
2 Weeks	0.89%	0.37%	53.33%	23.93%	-14.16%
1 Month	0.65%	3.14%	56.82%	18.71%	-19.93%

Next earnings: July 26, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Month	Avg Return	Win Rate	Samples
Jan	3.1%	63.6%	11
Feb	5.1%	58.3%	12
Mar	3.0%	41.7%	12
Apr	-3.1%	41.7%	12
May	-0.3%	36.4%	11
Jun	2.1%	63.6%	11
Jul	0.0%	63.6%	11
Aug	8.5%	72.7%	11
Sep	4.0%	63.6%	11
Oct	-1.0%	45.5%	11
Nov	4.7%	81.8%	11
Dec	4.2%	54.5%	11

Day-of-Week Tendencies

Day	Avg Return	Win Rate	Samples
Monday	0.03%	44.9%	532
Tuesday	0.28%	51.0%	586
Wednesday	0.03%	49.6%	583
Thursday	0.19%	50.0%	574
Friday	0.15%	50.3%	571

Insider Transactions — Smart Summary

Total insider ownership: 0.8%

Founder-led management: Jan Møller Mikkelsen (President and CEO)

12-Month Insider Activity Summary

Total Filings	1
Net Value	-$4.6M
Net Shares Change	-19,460
% of Float	-0.0%
C-Suite Filings	1
Clusters Detected	0

Key Insiders

Name	Title	Net Value	Filings	Activity
JENSEN FLEMMING STEEN	EVP and Product Supply and Quality	-$4.6M	1	1 sell

Significant Filings

Date	Insider	Title	Net Value	Price After
2026-05-12	JENSEN FLEMMING STEEN	EVP and Product Supply and Quality	-$4.6M	Transaction at $238.49, now +0.5%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Ascendis Pharma AS (ASND) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ASND on Trend Edge →

ASND — Ascendis Pharma AS

About Ascendis Pharma AS

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (45 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Significant Filings

AI Consult Analysis

ASND — Ascendis Pharma AS

About Ascendis Pharma AS

Trend Edge Proprietary Indicators

Key Metrics

Financial History

Annual Revenue & Earnings History

Recent Quarterly Revenue & Net Income

Ownership & Float

Current Moving Averages

Volume Shelves — Support & Resistance

Historical Earnings Reactions (45 events)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Day-of-Week Tendencies

Top Institutional Holders

Insider Transactions — Smart Summary

12-Month Insider Activity Summary

Key Insiders

Significant Filings

AI Consult Analysis

Related Biotechnology Stocks